Later, the Treat to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) trial revealed more harm in high levels of Hb and influenced the international guidelines on anemia to recommend a hemoglobin of 11 to 12 g/dL in all patients CKD dialysis and non-dialysis dependent, with or without diabetes [11–13]. The gene discussed is GSTM1; the disease is anemia.